TokenPost topic

Small Cell Lung Cancer

1 TokenPost story is tagged Small Cell Lung Cancer. The newest appear first.

Latest Small Cell Lung Cancer stories

• Amgen Reports 58% Lower Death Hazard in Lung Cancer Trial

  Median overall survival was 21.1 months with tarlatamab and durvalumab, compared with 12.7 months with durvalumab alone. The trial tested the combination as maintenance therapy after initial treatment.

  Oct 24, 2026, 3:26 PM EDT · Business